论文部分内容阅读
目的 为了寻找一种切实可行的检测方法及癌症患者体内肿瘤负荷的生物标志物。方法 用改良的Herman新方法对111例不同癌症患者的血清及部分组织进行了p16异常甲基化检测,同时对55例患者作了突变K-ras基因的检测作为比较。结果 各期住院患者血清及癌组织均在50％左右,与对照组比较皆有显著性差异(P<0.05)。癌与癌旁组织之间差异不明显。早期 癌血清与组织无明显差异。随着癌症病情的进展,阳性率亦随之上升;术后20天基本消失。突变K-ras基因的阳性率仅为30％,较前者明显低,如二者联合应用可提高阳性率13％。结论 改进MSP法检测血清中异常甲基化,与突变K-ras基因检测联合用,是一种行之有效的方法。
The purpose of this study was to find a practical method of detection and biomarkers of tumor burden in cancer patients. Methods A modified Herman new method was used to detect the abnormal methylation of p16 in serum and some tissues in 111 cases of different cancer patients. Meanwhile, 55 patients were tested for the mutation K-ras gene as a comparison. Results The serum and cancerous tissues of all inpatients were all about 50%, which were significantly different from the control group (P <0.05). The difference between cancer and paracancerous tissues is not obvious. Early cancer serum and tissue no significant difference. With the progress of cancer, the positive rate also increased; almost disappeared after 20 days. The positive rate of mutant K-ras gene was only 30%, which was significantly lower than the former, and the combination of the two could increase the positive rate of 13%. Conclusion The improved MSP method for detecting abnormal methylation in serum is an effective method in combination with mutation of K-ras gene.